Biosimilar Pricing and Competition: How Political Visibility Shapes Biologic Pricing After Loss of Exclusivity Introduction Biologics have reshaped the treatment landscape across a broad Read More »
Navigate access policies European Hospital Exemption Pathways for ATMPs : Implementation and Impact Read More
Navigate access policies Using the Hospital Exemption Pathway to improve patient access to ATMPs in Europe Read More
Define Your Value Strategy Fast-track reimbursement in Europe: Six reasons why manufacturers don’t use it Read More
Communicate the value A tailored approach to estimate the outlook of the gene therapy market Read More
Define Your Value Strategy More than just price cuts: Improving access to essential cancer drugs in low and lower-middle-income countries Read More
Navigate access policies How should pharmaceutical companies prepare for the upcoming joint EU HTA? Read More
